Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by DrHolidayon Jun 27, 2018 12:49pm
129 Views
Post# 28237703

Higher Highs Coming!

Higher Highs Coming!Today's AGM will be a very positive meeting, and I can imagine that those in attendance will be celebrating with champagne. Cheers and a toast to ICO managment for successfully passing phase one trials. This issue of non-toxicity I mentioned yesterday is indeed a very big issue when it comes to the adoption of Oral B Amphotericin which is likely to replace the injectable dose which is a product owned by Gilead. Could Gilead be in talks with ICO on moving the company forward to phase two trials on a joint collaboration? 

Or is AstraZeneca ICO's sweetheart partner? 
So, ICO is now the most beautiful girl at the dance, and can choose who to partner with.
May I have this dance?
Hold on tight to your shares and your dreams because ICO is going to make a series of higher highs on the strength of it's drug development pipeline. Congratulations to longs.

DOC.
<< Previous
Bullboard Posts
Next >>